Prolozone Therapy: What the Evidence Actually Says An Evidence-Based Review for Clinicians and Clients
Yoon Hang Kim MD
Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician
About Dr. Kim
Yoon Hang Kim MD is board-certified in preventive medicine with more than 20 years of clinical experience. A fellowship-trained integrative medicine physician through the University of Arizona’s Osher Center under Dr. Andrew Weil, he holds certifications in preventive medicine, medical acupuncture, and integrative and holistic medicine. Dr. Kim specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold-related illness. He is the author of eight books and more than 25 peer-reviewed articles.
Professional: www.yoonhangkim.com | Clinical: www.directintegrativecare.com
Introduction
If you’ve been living with chronic joint or musculoskeletal pain, you may have come across the term prolozone during your own research. It sounds promising—a therapy that combines the healing stimulus of prolotherapy with the oxygenating power of ozone gas. But what does the science actually say? And how should a thoughtful clinician or informed client evaluate the claims?
This article takes an honest, evidence-based look at prolozone therapy: what it is, how it works in theory, what the published literature supports, and where the gaps remain. My goal is not to sell you on a treatment or steer you away from one. It is to give you the information you need to have a real conversation with your provider.
An important distinction upfront: Much of the published research on ozone injection therapy studies intra-articular ozone gas alone—not the multi-component “prolozone” cocktail that many practitioners use. This article addresses both bodies of evidence, clearly separated, because the distinction matters scientifically. You cannot confidently infer efficacy of a proprietary multi-component protocol from studies of ozone gas alone, and vice versa.
What Is Prolozone Therapy?
Prolozone is a portmanteau—proliferation plus ozone—coined by Frank Shallenberger, MD, a physician who combined principles from three existing therapies: neural therapy, prolotherapy, and medical ozone therapy.1 In practice, the technique involves injecting a mixture of medical-grade ozone/oxygen gas along with a local anesthetic (typically procaine or lidocaine), vitamins (such as B-complex or methylcobalamin), minerals (such as magnesium), and sometimes a proliferant solution into joints, ligaments, or soft tissue.2
The idea is to address chronic pain at multiple levels simultaneously. The local anesthetic provides immediate pain relief and may help restore membrane potentials in damaged tissue (a concept borrowed from neural therapy). The nutrient cocktail aims to support the local biochemical environment. And the ozone gas—according to proponents—acts through redox signaling mechanisms that may modulate inflammation and support tissue repair.2,3
Prolozone is distinct from standard prolotherapy in one important respect: conventional prolotherapy relies on a controlled inflammatory response (typically triggered by hypertonic dextrose) to stimulate repair. Prolozone, by contrast, relies on ozone-mediated biochemical signaling rather than deliberate inflammation—which may explain why clients typically report less post-injection soreness.1
Proposed Mechanisms of Action
Understanding the theoretical basis of prolozone requires a brief look at what medical ozone does at the biochemical level. The proposed mechanisms are plausible but still being validated in clinical settings:
- Moderate oxidative stress and Nrf2 activation. Ozone introduces a controlled oxidative challenge. At moderate doses, this appears to activate the nuclear transcription factor Nrf2, which upregulates endogenous antioxidant enzymes and cytoprotective proteins. This is sometimes compared to the hormetic benefit of exercise—a mild stressor that strengthens the system’s defenses.4
- Anti-inflammatory cytokine modulation. Preclinical and mechanistic studies suggest that low-dose ozone can downregulate pro-inflammatory cytokines while enhancing anti-inflammatory mediators, potentially shifting the local tissue environment away from chronic inflammation.4,5
- Redox signaling rather than simple oxygenation. Ozone is a highly reactive oxidant that rapidly reacts with biological substrates rather than functioning simply as an oxygen-delivery therapy. Its proposed therapeutic effects are generally framed around redox signaling, modulation of inflammatory pathways, and adaptive antioxidant responses. The clinical relevance of these mechanisms remains uncertain.4,5
- Collagen stimulation. This is perhaps the most heavily marketed claim. While some proponents assert that prolozone can regenerate cartilage, the controlled clinical evidence for this specific claim remains limited. It is more accurate to say that ozone may support connective tissue repair processes, but calling this “cartilage regeneration” overstates what has been demonstrated in peer-reviewed trials (see the evidence section below for important recent nuance).
These mechanisms are biologically plausible but are drawn largely from preclinical work and mechanistic reviews. Translating them into consistent, measurable clinical outcomes is where the story gets more complicated.
What the Clinical Evidence Actually Shows
Note on terminology: The published literature includes studies of (A) intra-articular oxygen–ozone therapy alone and (B) multi-component prolozone protocols combining ozone with other agents. These are addressed separately below, because the evidence for one does not automatically apply to the other.
A. Evidence for Intra-Articular Oxygen–Ozone Therapy
Farpour et al. (2021) — Ozone Prolotherapy vs. Hypertonic Saline
This randomized clinical trial compared intra-articular ozone prolotherapy to hypertonic saline prolotherapy in 34 adults with knee osteoarthritis. Both groups improved on WOMAC pain, stiffness, and function scores. However, the difference between the two groups was not statistically significant (pain: p = 0.465; stiffness: p = 0.656; function: p = 0.376).6
Clinical takeaway: Both interventions helped, but the addition of ozone did not produce a measurable advantage over saline prolotherapy alone. This is a small trial, but the finding is worth noting.
Sconza et al. (2020) — Systematic Review of RCTs
This systematic review in Arthroscopy examined randomized controlled trials of oxygen–ozone therapy for knee osteoarthritis. The authors concluded that ozone therapy demonstrated encouraging effects in pain control and functional recovery in the short to medium term, while also noting a good safety profile. They cautioned that the available evidence was still limited by small sample sizes and methodological variability.7
Intra-Articular Ozone Meta-Analysis (2019)
Published in Complementary Therapies in Medicine, this meta-analysis of 10 studies found that intra-articular ozone therapy significantly attenuated pain in knee osteoarthritis compared to controls. However, a critical appraisal by Herrera-Peco et al. (2020) raised methodological concerns about some of the included studies and the overall heterogeneity of the data.8,9
Javadi Hedayatabad et al. (2020) — Ozone vs. Hyaluronic Acid
This meta-analysis compared ozone to hyaluronic acid (HA) injections for knee osteoarthritis. The result: no significant difference between the two for pain reduction or functional improvement. The authors interpreted these findings as raising the possibility that ozone’s effects may be largely nonspecific—noting that since previous studies have shown comparable results between HA and placebo, ozone may fall in a similar category.10
Clinical takeaway: That interpretation deserves attention, but it is important to note that indirect comparison with placebo does not establish equivalence to placebo. The finding is suggestive, not conclusive.
Lino et al. (2024) — Umbrella Review of Systematic Reviews
Published in Frontiers in Physiology, this umbrella review examined eight systematic reviews covering 15 RCTs and 3,685 clients. It found beneficial effects for pain control and a low prevalence of minor adverse events. Ozone was superior to placebo in some analyses but generally not superior to active comparators. Critically, using the AMSTAR2 quality assessment tool, all eight reviews received critically low confidence ratings—meaning even the evidence we have needs to be interpreted cautiously.11
Time-Effect Meta-Analysis (2026)
A recent systematic review and meta-analysis in Frontiers in Pain Research examined the temporal efficacy of intra-articular ozone therapy across multiple follow-up time points. The authors found that ozone therapy effectively alleviates pain and improves joint function in the short term (1–2 months), with effects peaking at approximately 2 months and declining thereafter. The study characterized the overall evidence base as still limited by heterogeneity, risk of bias, inconsistent protocols, and very limited placebo-controlled long-term data.12
Ozone vs. Corticosteroid Systematic Review (2025–2026)
A recent systematic review and meta-analysis examining ozone versus corticosteroid injections reported improvement in knee OA pain with ozone.13 This adds to the emerging picture that ozone may be comparable to or modestly better than some active comparators for short-term pain control, though the same caveats about evidence quality apply.
B. Evidence for Multi-Component Prolozone Protocols
Until recently, there were no rigorous trials evaluating a combined prolozone formulation as it is actually used in clinical practice. That has begun to change.
Prolozone M RCT (2026)
A 2026 randomized, double-blind, placebo-controlled trial of 180 clients evaluated a combined formulation involving hypertonic dextrose, ozone, and magnesium (called “Prolozone M”). The study reported greater WOMAC pain improvement at 24 weeks compared to corticosteroid treatment, and described radiographic findings interpreted as preliminary evidence of possible chondroprotection.14
Clinical takeaway: This is the most important addition to the evidence base in recent years, because it is the first rigorous trial to evaluate a multi-component prolozone protocol rather than ozone gas alone. The radiographic findings are preliminary and require independent replication—they do not establish cartilage regeneration or disease modification. But they materially change the statement that controlled trials provide essentially no evidence relevant to structural effects.
Summing Up the Evidence
Here’s where I land after reviewing the literature through 2026:
- Intra-articular ozone therapy for knee osteoarthritis appears to reduce pain and improve function in the short to medium term. That much is fairly consistent across reviews.
- Whether the ozone component adds meaningful benefit beyond what prolotherapy, hyaluronic acid, corticosteroids, or even placebo can achieve remains an open question. Multiple head-to-head comparisons have failed to show consistent superiority for ozone over active comparators.
- Controlled evidence does not establish clinically meaningful cartilage regeneration. A recent randomized trial reported preliminary radiographic findings interpreted as possible chondroprotection, but these findings require independent replication and do not establish cartilage restoration or disease modification.
- Published knee-OA trials generally report few serious adverse events and mostly transient local reactions. However, study sizes are insufficient to reliably quantify uncommon complications.
- Evidence supporting ozone alone cannot automatically be extrapolated to every multi-component prolozone protocol, and vice versa. This distinction is essential when evaluating claims.
- The overall quality of the evidence remains limited by small sample sizes, inconsistent protocols, risk of bias, and lack of standardization.
Practical Considerations for Clients
Protocol: Regimens vary considerably. Some practitioners offer 1–3 sessions (particularly when combining ozone with PRP), while others recommend 3–8 sessions spaced 2–6 weeks apart. There is no universally standardized protocol.2,15
Cost and insurance: Because prolozone is investigational and lacks established reimbursement pathways, it is commonly self-pay. Clients should expect to pay several hundred dollars per session out of pocket. Coverage should be verified with the individual payer, but most will not cover an unapproved therapy.2,3
Side effects: Published trials generally report transient local reactions—soreness, bruising, and swelling at the injection site. Rare but possible complications include infection, allergic reactions to the anesthetic or nutrient additives, and injury to surrounding structures. Existing studies are not large enough to reliably quantify uncommon harms.2,16
Contraindications reported in treatment protocols: Some ozone-treatment protocols list uncontrolled hyperthyroidism, thrombocytopenia, severe cardiovascular instability, seizure disorders, and pregnancy as contraindications. These are proposed contraindications within treatment protocols, not contraindications established through high-quality evidence or regulatory guidance.2,15
A Note for Clinicians
If you are considering offering prolozone in your practice, here are several points worth your attention:
- Informed consent is essential. Consent documents should clearly state that this therapy is investigational and unapproved—not merely “off-label.” Ozone gas is not an FDA-approved injectable therapeutic product. Federal regulation (21 CFR § 801.415) classifies ozone as a toxic gas with no known useful medical application in specific, adjunctive, or preventive therapy. While the clinical picture may be evolving, the regulatory classification has not changed.
- Keep your claims evidence-calibrated. Saying that prolozone may help reduce joint pain and improve function is supportable. Saying that it regenerates cartilage is not yet established—and that kind of overstatement erodes trust. Even the most recent trial showing preliminary radiographic findings describes them as possible chondroprotection requiring replication, not regeneration.
- Check your regulatory and malpractice standing. Confirm your state medical board’s position on ozone injection therapies and verify that your malpractice carrier covers this modality before incorporating it into practice.
- Document thoroughly. As with any investigational therapy, meticulous documentation of the clinical rationale, the injection contents, the informed consent discussion, and the client’s response is both good medicine and sound risk management.
The Bottom Line
Prolozone therapy is not quackery—but it’s not a miracle either. It sits in a gray zone that is common in regenerative and integrative medicine: biologically plausible mechanisms supported by promising but limited clinical data, surrounded by marketing claims that have outrun the evidence.
Current evidence suggests that intra-articular oxygen–ozone therapy may reduce pain in knee osteoarthritis over the short to intermediate term. Some randomized trials and meta-analyses demonstrate benefit compared with placebo or corticosteroid injections, while comparisons with hyaluronic acid, dextrose prolotherapy, and other injection therapies generally have not shown consistent superiority.
It is also important to distinguish intra-articular ozone therapy from “prolozone,” which may combine ozone with dextrose, anesthetics, magnesium, vitamins, or other agents. A recent randomized trial of a dextrose–ozone–magnesium formulation reported clinically meaningful pain improvement and preliminary radiographic findings interpreted as possible chondroprotection, but these findings require independent replication and do not establish cartilage regeneration.
For selected clients with knee osteoarthritis who remain symptomatic despite established conservative management, intra-articular ozone-containing therapy may be considered an investigational option after thorough discussion of the uncertain comparative benefit, lack of proven disease modification, cost, and regulatory status.
What it deserves is more rigorous, standardized, independently replicated research with longer follow-up. What it does not deserve is either uncritical promotion or reflexive dismissal.
Work with Dr. Kim
Dr. Kim offers membership-based, insurance-free integrative and functional medicine telemedicine consultations. If you are interested in discussing prolozone therapy or other evidence-based approaches to chronic pain, autoimmune conditions, or complex medical concerns, visit www.directintegrativecare.com to learn more about becoming a client.
References
1. Shallenberger F. Prolozone™ — Regenerating joints and eliminating pain. Journal of Prolotherapy. 2011;3(2):630–638.
2. Ultra Wellness Center. Prolozone fact sheet. 2025. Available at: https://www.ultrawellnesscenter.com/2025/05/29/prolozone-fact-sheet/
3. Barr Center. The healing power and benefits of prolozone therapy. Available at: https://barrcenter.com/the-healing-power-and-benefits-of-prolozone-therapy/
4. Sagai M, Bocci V. Mechanisms of action involved in ozone therapy: Is healing induced via a mild oxidative stress? Med Gas Res. 2011;1:29. doi:10.1186/2045-9912-1-29.
5. Viebahn-Haensler R, León Fernández OS. Ozone in medicine: The low-dose ozone concept and its basic biochemical mechanisms of action in chronic inflammatory diseases. Int J Mol Sci. 2021;22(15):7890. doi:10.3390/ijms22157890.
6. Farpour HR, Ashraf A, Hosseini SS. The efficacy of ozone prolotherapy compared to intra-articular hypertonic saline injection in reducing pain and improving the function of patients with knee osteoarthritis: A randomized clinical trial. Evid Based Complement Alternat Med. 2021;2021:5579944. doi:10.1155/2021/5579944.
7. Sconza C, Respizzi S, Virelli L, Vandenbulcke F, Iacono F, Kon E, Di Matteo B. Oxygen–ozone therapy for the treatment of knee osteoarthritis: A systematic review of randomized controlled trials. Arthroscopy. 2020;36(1):277–286. doi:10.1016/j.arthro.2019.05.043.
8. Intra-articular ozone therapy efficiently attenuates pain in knee osteoarthritic subjects: A systematic review and meta-analysis. Complement Ther Med. 2019;42:240–247. doi:10.1016/j.ctim.2018.11.023. [Note: First author requires verification against the original publication prior to final citation.]
9. Herrera-Peco I, Santillán-García A, Cuesta-Lozano D, et al. Critical appraisal of the systematic review and meta-analysis of intra-articular ozone therapy efficiency to attenuate pain in knee osteoarthritis. Complement Ther Med. 2020;54:102244. doi:10.1016/j.ctim.2019.102244.
10. Javadi Hedayatabad J, Kachooei AR, Taher Chaharjouy N, et al. The effect of ozone (O3) versus hyaluronic acid on pain and function in patients with knee osteoarthritis: A systematic review and meta-analysis. Arch Bone Jt Surg. 2020;8(3):343–354. doi:10.22038/abjs.2020.46925.2292.
11. Lino VTS, Marinho DS, Rodrigues NCP, Andrade CAF. Efficacy and safety of ozone therapy for knee osteoarthritis: An umbrella review of systematic reviews. Front Physiol. 2024;15:1348028. doi:10.3389/fphys.2024.1348028.
12. The time-effect relationship of intra-articular ozone injection for knee osteoarthritis: A systematic review and meta-analysis. Front Pain Res. 2026. doi:10.3389/fpain.2026.1843756.
13. Ozone injections reduce pain in knee osteoarthritis: A systematic review and meta-analysis. PMID: 41496305. [Verify full citation against original publication prior to final submission.]
14. Prolozone M therapy’s analgesic efficacy for managing moderate-to-severe knee osteoarthritis: A randomized, double-blind, placebo-controlled trial. PMID: 42804311. [Verify full citation against original publication prior to final submission.]
15. OMMDoc Hollywood. Prolozone therapy. Available at: https://www.ommdochollywood.com/prolozone-therapy.html
16. 180 Pain Relief Centers. Prolozone injection patient outcomes. Available at: https://www.180painreliefcenters.com/prolozone-injection-patient-outcomes/
17. Arnold FG. Prolozone: Regenerative medicine. Naturopathic Doctor News & Review. Available at: https://ndnr.com/?p=40346
Yoon Hang Kim MD is the author of MCAS: Epidemic in Plain Sight and LDN Primer, both available on Amazon, and is the founder of the LDN Support Group.